Specipig, CataloniaBio & HealthTech member, has expanded its facilities, in the Barcelona area, to a total surface area of 2,400 square metres in order to boost its capacity as a benchmark preclinical Contract Research Organization (CRO) in the biomedical sector. The company currently has three fully equipped operating sites, one analytical laboratory, research facilities and offices, and a team of over 20 qualified professionals.

Anaconda Biomed, a spin-off from the Vall d’Hebron Research Institute (VHIR) and members of CataloniaBio & HealthTech, has completed the clinical trial it was conducting for Advanced Neurovascular Access (ANA), its next-generation catheter. The product could hit the market next year.

The Girona-based company mjn-neuro is one of the start-ups benefiting from EIT Health’s Start-up Amplifier Instrument program, an initiative that helps start-ups gain access to new European markets. The 2.76 million euros grant will allow mjn-neuro to enter the European market with its mjn-SERAS device, the first product worldwide capable of warning in advance of a crisis of epilepsy.

The pharmaceutical company Gebro Pharma and the start-up HumanITcare have signed an agreement for the entry of the pharmaceutical company into the telemedicine sector, specifically in the monitoring of asthma patients. Both companies are members of CataloniaBio & HealthTech.

Onalabs has been recognized as an innovative technology company in the first edition of the DRAC Awards. The RAC1 station has organized the first edition of the DRAC Awards with the aim of recognizing the people, initiatives, organizations, and projects that have driven change and improvement in society and that have become a benchmark in the last year.

Asphalion announced the release of its 2022 Corporate Social Responsibility (CSR) plan, demonstrating its CSR commitment to meet this year’s sustainability goals built on three pillars: health and well-being, gender equality and responsible production and consumption. The plan highlights the priority areas where  Asphalion will set its focus. These are aligned with the 17 UN 2030 sustainable  development goals.

The spin-off INBRAIN  Neuroelectronics has signed an agreement for the exploitation and development of three patents and an industrial secret, of which the Barcelona Institute of Microelectronics (IMB-CNM) of the CSIC, the Institut Català de Nanociència i Nanotecnologia (ICN2), the Catalan Institution for Research and Advanced Studies (ICREA) and the CIBER (CIBER-BBN area). The Autonomous University of Barcelona (UAB) and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) are also holders. This is a technology transfer success in a  public-private collaboration with multiple research institutions.

El fons ICF Capital Expansió II ha invertit 2,5 milions d’euros a l’empresa gironina TECNIC Bioprocess Equipment Manufacturing especialitzada en el desenvolupament d’equips per processos biotecnològics. L’operació s’ha fet a través d’una ampliació de capital amb l’objectiu de millorar la competitivitat de l’empresa i impulsar el seu creixement internacional.

Integra Therapeutics, a biotechnology company that creates next generation gene writing tools, a CataloniaBio & HealthTech  member, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the €4.5 million Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures and completes its seed round in line with the company’s set goals.

DevsHealth, the deeptech companyand a CataloniaBio &HealthTech member, and FundacióLluita contra la Sida i les Malalties Infeccioses havestarted a joint project to design new molecules aimed against SARS-CoV-2, whichwill provide effective and affordable treatments and reduce the progression ofthe disease and severe cases. The joint project will allow both parties touse DevsHealth DeepTech processes to design new candidate molecules, as well asthe expertise in drug validation and evaluation provided by Fundació.This will increase the success rates and efficacy of the future drugs againstSARS-CoV-2.

The last two years have unquestionably made a difference in the biomedical and health sector, and Catalonia has not been an exception. The COVID-19 pandemic has highlighted the importance of a commitment to knowledge and innovation industry, the need to have a local industrial network, while acknowledging that biotechnology and medical technology is a rising sector. This atmosphere of optimism about the situation of the sector has been present in the celebration of the Night of CataloniaBio & Healthtech, the annual meeting of the health and life sciences sector in Catalonia, which was held this March 22 at the Palau de la Música in Barcelona. The event was attended by the Catalan Minister of Health, Josep Maria Argimon, and more than 250 members of the association, including entrepreneurs, executives, and investors in the sector.

CataloniaBio & HealthTech ha lliurat el Premi Bioèxit a la biotecnològica IMIDomics per l’exemplar translació entre la clínica i l’empresa i, en especial, per les fites  assolides en finançament durant el 2021 en l’àmbit de la biomedicina i  la salut a Catalunya. L’acte d’entrega s’ha celebrat aquest 22 de març en el marc de la Nit de CataloniaBio & HealthTech al Palau de la Música de Barcelona, al qual hi ha assistit el conseller de Salut, Josep Maria Argimon, i més de 250 membres de l’associació, entre emprenedors, executius i inversors del sector.

Vall d’Hebron University Hospital and the biotechnology company Goodgut, a HIPRA group company, both CataloniaBio  & HealthTech members, are launching a study to implement RAID-Dx, a non-invasive diagnostic test for irritable bowel syndrome (IBS). The study will be conducted with 300 patients with symptoms of the disease.

Aiming to create artificial organs and tissues for clinical application, the Production  and Validation Center for Advanced Therapies of the University of Barcelona (Creatio), will purchase and launch one of the first 4D laser-assisted  bioprinters in Europe. Creatio obtained a funding of 999,604 euros from the Ministry of Science and Innovation, within the call Equipamiento Científico-Técnico 2021. The University of Barcelona will become a worldwide reference in translational research in tissue engineering.

MOWWOT, a company specializing in medical devices for intestinal transit disorder, and a member of CataloniaBio &  HealthTech, has announced the closure of the first tranche of its Series  A investment round worth 1.05 million euros. This first tranche has involved USM Global Corporation, an investment vehicle that brings together several crowdfunding investors from Capital Cell, ENISA, 4M Medical GmbH and other German business angels.

Vytrus Biotech, a company specializing in active ingredients derived from plant stem cells for the cosmetics industry, and a CataloniaBio &  HealthTech member, went public this Tuesday, March 15 and closed its  first day with an increase in its value by more than 25% in its first trading  day on BME Growth, the SME exchange.

Specipig, a CataloniaBio & HealthTechmember, closed 2021 achieving 150 preclinical research projects andreinforcing its position as the reference preclinical ContractResearch Organisation (CRO) for the globalpharmaceutical, biotechnology and medical technology industry.

CataloniaBio & HealthTech s’adhereix al Parc Científic de Barcelona i a diverses entitats ubicades al PCB en l’emissió del següent comunicat en suport al poble ucraïnès davant la invasió de Rússia.

The 2022 edition of the Mobile World Congress (MWC) is beginning to pick up the pre-pandemic pace. Still with the mask as a constant reminder, this year's edition of the MWC has closed its doors with more than 60,000 attendees from nearly 200 different countries, figures that have exceeded the organization's initial scenario.

Ysios Capital, gestora europea de venture capital al sector de les ciències de la vida, membre de CataloniaBio & HealthTech, ha anunciat el nomenament de Thomas Harth com a Principal. Thomas se suma a Ysios per reforçar l’equip d’anàlisi i identificació de noves inversions. En el rol de Principal també representarà els interessos dels fons d’Ysios als consells d’administració de les companyies participades.